$3.26
2.40% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US83558L1052
Symbol
SNOA

Sonoma Pharmaceuticals, Inc. Stock price

$3.26
-0.68 17.26% 1M
-0.03 0.91% 6M
+0.57 21.19% YTD
+0.42 14.79% 1Y
-33.79 91.20% 3Y
-129.34 97.54% 5Y
-1,041.64 99.69% 10Y
-49,136.74 99.99% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.08 2.40%
ISIN
US83558L1052
Symbol
SNOA
Industry

Key metrics

Basic
Market capitalization
$5.6m
Enterprise Value
$2.6m
Net debt
positive
Cash
$3.0m
Shares outstanding
1.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.3 | 0.3
EV/Sales
0.2 | 0.2
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
32.2%
Return on Equity
-78.4%
ROCE
-32.7%
ROIC
-36.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$16.9m | $17.6m
EBITDA
$-3.0m | -
EBIT
$-3.1m | $-2.8m
Net Income
$-3.5m | $-2.2m
Free Cash Flow
$-2.4m
Growth (TTM | estimate)
Revenue
25.0% | 23.0%
EBITDA
27.7% | -
EBIT
27.1% | 23.6%
Net Income
5.7% | 36.1%
Free Cash Flow
-53.6%
Margin (TTM | estimate)
Gross
37.7%
EBITDA
-17.6% | -
EBIT
-18.4%
Net
-20.5% | -12.6%
Free Cash Flow
-13.9%
More
EPS
$-2.1
FCF per Share
$-1.4
Short interest
2.7%
Employees
10
Rev per Employee
$1.4m
Show more

Is Sonoma Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Sonoma Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Sonoma Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
17 17
25% 25%
100%
- Direct Costs 11 11
27% 27%
62%
6.38 6.38
22% 22%
38%
- Selling and Administrative Expenses 7.49 7.49
0% 0%
44%
- Research and Development Expense 2.01 2.01
1% 1%
12%
-2.98 -2.98
28% 28%
-18%
- Depreciation and Amortization 0.14 0.14
13% 13%
1%
EBIT (Operating Income) EBIT -3.12 -3.12
27% 27%
-18%
Net Profit -3.48 -3.48
6% 6%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Sonoma Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonoma Pharmaceuticals, Inc. Stock News

Neutral
Accesswire
8 days ago
BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced that Reliefacyn® Advanced...
Neutral
Accesswire
14 days ago
BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it wi...
Neutral
Accesswire
17 days ago
Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year U.S. revenue increased 115% for the quarter and 86% for the six months ended September 30, 2025 compared to same periods last year Net loss per share decreased 46% for the quarter and 42% for the six months ended September 30, 2025 compared to same periods last year BOUL...
More Sonoma Pharmaceuticals, Inc. News

Company Profile

Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.

Head office United States
CEO Amy Trombly
Employees 10
Founded 1999
Website sonomapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today